Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Product › Details

HCV-796

	Next higher product group	polymerase inhibitor
	Status	2008-04-16 development p2 end–negat
	Organisation	Wyeth (NYSE: WYE)
	Group	Pfizer (Group)
	Organisation 2	ViroPharma Inc. (Nasdaq: VPHM)
	Today	Shire (Group)
	Group	Takeda (Group)

Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for virostatic agent

[1] ProBioGen AG. (3/13/24). "Press Release: ProBioGen Partners with Mapp Biopharmaceutical, Inc. for Groundbreaking Development of Afucosylated Antibody against Marburg Virus Disease Using GlymaxX Technology". Berlin....
[2] Exscientia plc. (12/5/23). "Press Release: Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza". Oxford....
[3] Abivax S.A.. (10/24/23). "Press Release: Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market". Paris....
[4] Abivax S.A.. (10/20/23). "Press Release: Abivax Announces the Pricing of Its Initial Public Offering on the Nasdaq Global Market". Paris....
[5] Abivax S.A.. (9/29/23). "Press Release: Abivax Files Registration Statement for Proposed Initial Public Offering in the United States". Paris....
[6] AiCuris Anti-infective Cures AG. (8/23/23). "Press Release: AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of Prevymis (letermovir) in Second Indication". Wuppertal....
[7] Abivax S.A.. (8/23/23). "Press Release: Abivax Appoints Patrick Malloy as Senior Vice President Investor Relations". Paris....
[8] Abivax S.A.. (8/21/23). "Press Release: Abivax Secures Up to EUR 150M from Two Structured Debt Financing Transactions". Paris....
[9] Abivax S.A.. (7/11/23). "Press Release: Abivax Announces the Appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors". Paris....
[10] AiCuris Anti-infective Cures AG. (7/6/23). "Press Release: AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients". Wuppertal....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]